San Diego, United States
Kinnate Biopharma Inc., founded in 2018 and headquartered in the United States, is a clinical-stage precision oncology company with a compelling mission encapsulated in their slogan, "Inspiring Hope to Those Battling Cancer." The company operates within the Biopharma, Biotechnology, Health Care, and Health and Wellness industries, focusing on innovative approaches to targeted cancer therapies.
Kinnate's strategic core lies in developing medicines aimed at known oncogenic drivers lacking approved drugs, addressing challenges like non-responsiveness and resistance. They currently have two clinical programs that target solid tumors with RAF, NRAS, and FGFR-driven alterations, with additional candidates in the pipeline propelled by the Kinnate Discovery Engine.
In a strong indicator of industry trust and potential, Kinnate secured a $120.00M acquisition investment from XOMA as of 01 February 2024. This financial support is positioned to accelerate their promising pipeline, driving further developments in much-needed cancer therapeutics.
